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ABSTRACT
Background: Macrophage migration inhibitory factor (MIF)
has recently emerged as an important cytokine possibly
linking rheumatoid arthritis (RA) and atherogenesis.
Because atherogenesis is accelerated in RA this study was
conducted to investigate whether anti-tumour necrosis
factor (TNF) therapy could lead to sustained downregulation
of systemic MIF levels and improvement in lipid profiles.
Methods: Fifty RA patients with active disease (disease
activity score in 28 joints (DAS28) >3.2), who started
adalimumab therapy at 40 mg every other week, were
included. At baseline, weeks 16 and 52 serum levels of
MIF and lipids were assessed. In addition, the DAS28 and
serum C-reactive protein (CRP) levels and erythrocyte
sedimentation rate (ESR) were determined.
Results: After 16 weeks of adalimumab therapy, both
DAS28 and MIF levels were significantly decreased
(p,0.001 and p=0.020, respectively). This was
sustained up to week 52 (p,0.001 and p=0.012,
respectively). CRP levels and ESR were significantly
reduced after 16 and 52 weeks of adalimumab therapy
(p,0.001). High-density lipoprotein cholesterol levels
increased at week 16 (p,0.001), but returned to baseline
at week 52. Apolipoprotein (apo) A-I levels increased at
week 16 (p,0.001) and remained stable (p=0.005).
This resulted in an improved apo B/A-I ratio.
Conclusions: The results underline the sustained down-
regulation of MIF as a potential new mechanism by which
anti-TNF therapy might reduce vascular inflammation, and
as such perhaps cardiovascular morbidity in RA patients.
This hypothesis is supported by an improved apo B/A-I ratio
as well as reduced CRP levels in these patients.
The atherosclerotic process is accelerated in
patients with rheumatoid arthritis (RA), resulting
in increased cardiovascular mortality when com-
pared with the general population. It has been
suggested that the chronic systemic inflammatory
state in RA enhances atherogenesis
1 over and above
the presence of traditional risk factors (eg, diabetes,
smoking, obesity, dyslipidaemia). Inflammatory
mediators from the synovium and perhaps other
sites can be released into the circulation where they
can alter the function of various tissues, such as
skeletal muscle, liver and vascular endothelium.
This in turn may induce an array of proatherogenic
changes, including insulin resistance, characteristic
dyslipidaemia and endothelial dysfunction.
2
Moreover, circulating inflammatory mediators
may also stimulate leucocytes and smooth muscle
cells within the atherosclerotic plaque thereby
promoting plaque growth or rupture.
3
Macrophage migration inhibitory factor (MIF)
has emerged as a cytokine linking RA and
atherogenesis.
4 The association of coronary heart
disease (CHD) with a haplotype containing the
rs755622C allele, which has been reported before to
increase the susceptibility to various inflammatory
conditions, supports the notion that MIF plays a
role in inflammation and atherogenesis, although
there was no difference in MIF serum levels
between patients with incident CHD and indivi-
duals without such disease during follow-up in a
population-based case–cohort study.
5 However, in
another prospective population study in appar-
ently healthy volunteers, elevated levels of MIF
were associated with an increased risk of future
coronary artery disease.
6 The receptors CXCR2 on
monocytes and CXCR4 on T cells have been
identified as the functional receptors for MIF.
7
Interaction of CXCR2 with MIF on aortic
endothelial cells was shown to induce monocyte
arrest. Similarly, the interaction of CXCR4 with
MIF resulted in the arrest of T cells. MIF can also
induce the secretion of tumour necrosis factor
(TNF) by macrophages and, conversely, TNF is
able to augment MIF production.
8 In an animal
model of atherosclerosis, MIF blockade reduced
plaque infiltration by monocytes and T cells, and
even led to plaque regression.
7 Recent studies have
demonstrated that MIF secretion by dendritic cells
can be regulated by Toll-like receptors (TLR).
9 In
the atherosclerotic lesion, TLR4 in particular has
been shown to be expressed by residing macro-
phages and dendritic cells.
10 11 When TLR4 is
triggered by its ligands (for example lipopolysac-
charide), various cytokines, including TNF, IL-12,
IL-23 and MIF, can be secreted, thereby further
enhancing the inflammatory response.
91 0
Together, the available data indicate that MIF
exerts chemokine-like functions and is an impor-
tant regulator of inflammatory cell recruitment
and atherogenesis. It is thus conceivable that
reducing MIF might be a potential therapeutic
target for patients with atherosclerosis.
The notion that inflammation in RA and
atherogenesis is linked is supported by data
suggesting that reducing disease activity by
adequate disease-modifying antirheumatic drug
(DMARD) therapy may result in a decrease in
cardiovascular mortality.
12 13 TNF blockade could
diminish the increased cardiovascular risk asso-
ciated with RA by attenuating not only local but
also systemic inflammation associated with
atherogenesis.
14 15
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1316 Ann Rheum Dis 2009;68:1316–1321. doi:10.1136/ard.2007.086728To explore the relationship between inflammation and
factors involved in atherogenesis, we investigated the early
and long-term effects of anti-TNF therapy on serum MIF levels
and known risk factors such as C-reactive protein (CRP) levels
and the lipid profile in RA patients.
PATIENTS AND METHODS
Patients
Fifty RA patients with active disease (disease activity score in 28
joints (DAS28) >3.2) were included in the study. All patients
received adalimumab 40 mg subcutaneously every other week
in combination with methotrexate in a stable dose for at least
8 weeks. The concomitant use of prednisone ((10 mg/day)
and non-steroidal anti-inflammatory drugs was allowed if stable
for at least one month. Approval for this study was obtained
from the institutional ethics review committee at the Academic
Medical Center/University of Amsterdam. All participants gave
written informed consent.
Clinical assessments
RA disease activity was assessed at baseline and weeks 16 and 52
after the start of adalimumab treatment using the DAS28. Clinical
response was evaluated by the EULAR response criteria. For
comparison of data between responders (good and moderate) and
non-respondersweusedresponsemeasuredatweek16.Inaddition,
the presence of extra-articular manifestations (such as vasculitis,
nodules and pleuritis) was noted before entry into the study.
Cardiovascular risk factor profiles
In the assessment of cardiovascular risk factors the following
data were recorded: medical history including cardiovascular
events, smoking (current smoker, ever smoker) and current
medication, hypertension, dyslipidaemia, diabetes and body
mass index (BMI; kg/m
2).
Lipid profiles
Serum total cholesterol, high-density lipoprotein (HDL), and
low-density lipoprotein (LDL) cholesterol, triglyceride and
lipoprotein (a) (Lp(a)) levels were assessed by standard
laboratory techniques. Apolipoprotein (apo) A-I and apo B
levels were measured by an automated nephelometric assay
using an array protein system nephelometer (Beckman,
Mijdrecht, The Netherlands). In addition, erythrocyte sedimenta-
tion rate (ESR; mm/h) and CRP levels (mg/l) were determined.
Blood was drawn from patients while fasting at baseline and at16
and 52 weeks after initiation of adalimumab therapy. All values
were determined by the GLP certified routine clinical chemistry
laboratory at the Academic Medical Center in Amsterdam.
MIF ELISA
Natural serum MIF levels (pg/ml) were determined with a
commercial quantitative sandwich-enzyme immunoassay
(human MIF, DY289, R&D Systems Inc, Minneapolis,
Minnesota, USA). The assay was performed according to the
manufacturer’s instructions. Fasting serum samples were stored
at 280uC and analysed all at once.
Statistical analysis
A paired t test or the Wilcoxon signed ranks test, whichever was
appropriate, was used to determine significant changes from
baseline. Probability values less than 0.05 were considered
statistically significant in a two-tailed test. This exploratory
Table 1 Baseline patient characteristics
All
n=5 0
Responders
n=3 9
Non-responders
n = 11 p Value
Age, years (SD) 51 (13) 51 (12) 47 (17) 0.331
Female (%) 38 (76) 28 (72) 10 (91) 0.190
Disease duration, months (IQR) 59 (33–145) 61 (29–149) 54 (34–142) 0.935
Erosive disease (%) 33 (66) 26 (67) 7 (64) 0.851
Rheumatoid factor positive (%) 36 (72) 29 (74) 7 (64) 0.484
Anti-CCP positive (%) 35 (70) 28 (72) 7 (64) 0.602
Extra articular manifestations (IQR) 14 (28) 12 (31) 2 (18) 0.412
DAS28 (SD) 5.6 (1.1) 5.7 (1.1) 5.3 (0.8) 0.225
BMI, kg/m
2 (SD) 27 (6.3) 27 (6.3) 26 (6.7) 0.557
Smokers, current (%) 12 (24) 10 (26) 2 (18) 0.609
Smokers, ever (%) 31 (62) 27 (69) 4 (36) 0.047*
SBP, mm Hg (SD) 132 (15) 133 (16) 129 (12) 0.606
DBP, mm Hg (SD) 80 (9) 80 (9) 83 (8) 0.241
ESR, mm/h (IQR) 20 (11–35) 20 (11–35) 20 (15–36) 0.824
CRP, mg/l (IQR) 17 (5–20) 10 (4–22) 8 (5–16) 0.779
Diabetes mellitus type 2 (%) 4 (8) 4 (10) 0 (0) 0.268
Previous cardiovascular event (%) 4 (8) 3 (8) 1 (9) 0.687
Statin use (%) 6 (12) 5 (13) 1 (9) 0.717
Antihypertensive drug use (%) 16 (32) 13 (41) 3 (27) 0.704
Methotrexate, mg/week (SD) 18.4 (7.6) 18.0 (7.7) 19.5 (7.5) 0.508
Use of corticosteroids (%) 16 (32) 11 (28) 5 (45) 0.279
Prednisone dose, mg/day (SD) 7.8 (2.4) 7.8 (2.4) 8.0 (2.7) 0.268
Use of NSAID (%) 36 (72) 28 (78) 8 (73) 0.951
Mean values (SD), median and interquartile range (IQR) or percentages are shown.
*p Values ,0.05 (two-sided) are significant.
BMI, body mass index; CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, disease activity score in 28 joints; DBP,
diastolic blood pressure; ESR, erythrocyte sedimentation rate; NSAID, non-steroidal anti-inflammatory drug; SBP, systolic blood
pressure.
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Bonferroni correction. Independent samples t tests were used for
subanalysis to detect differences in baseline values or changes
after treatment between groups. Correlations were assessed
with the Pearson product-moment or Spearman rank-order
correlation coefficients, whichever was appropriate. Stepwise
backward multivariable linear regression analysis was used to
identify possible baseline predictors of change in MIF levels at
weeks 16 and 52. Because delta MIF levels had a skewed
distribution, values were rank-transformed before linear regres-
sion analysis. Baseline variables included in the analysis were
sex, BMI, MIF, CRP, triglyceride, total cholesterol and HDL
levels. Values are expressed as the mean (SD) or median and
interquartile range (IQR), whichever was appropriate. SPSS
12.0.2 for Windows was used.
RESULTS
Patients and clinical response
The baseline patient characteristics of 50 patients are shown in
table 1. The DAS28 score decreased significantly after 16 weeks
(DAS28 3.7, SD 1.2) and 52 weeks (3.4, SD 1.4) of adalimumab
therapy compared with baseline (5.6, SD 1.1; both p,0.001). At
week 16 all patients were evaluable for clinical response: 11
(22%) patients were EULAR non-responders, 25 (50%) were
moderate responders and 14 (28%) were good responders. At
week 52 there were 44 patients with an evaluable response, of
whom six (14%) were non-responders, 18 (41%) were moderate
responders and 20 (45%) were good responders. Six patients
dropped out of the study between 16 and 52 weeks follow-up
due to lack of efficacy in five patients and a serious adverse
event in one patient.
Pretreatment serum MIF levels
A large variability in MIF levels was observed between patients
varying from the lowest detectable concentration of 60 pg/ml
up to 6571 pg/ml. There was no significant relationship with
the use of low-dose corticosteroids or the dosage of methotrex-
ate, nor with clinical measures of disease activity at baseline
(data not shown).
Pretreatment apo A-I and HDL levels are inversely correlated
with systemic inflammation
There was a negative correlation between the pretreatment apo
A-I and CRP levels (r = 20.338, p=0.017) as well as ESR
(r = 20.347, p=0.014). Similarly, pretreatment HDL-choles-
terol correlated inversely with CRP levels and ESR (r = 20.290,
p=0.041 and r = 20.340, p=0.016, respectively).
Interestingly, higher pretreatment HDL levels correlated with
lower MIF levels before the initiation of adalimumab therapy
(r = 20.294, p=0.040). As expected, baseline LDL-cholesterol
was significantly lower in the six patients who used statins
compared with the other 44 who did not use a statin
(p=0.007); other lipoproteins did not differ between these
groups. All patients who used statins were known to have a
history of hypercholesterolaemia. Four of the six patients had had
a previous cardiovascular event, and all six were on concomitant
antihypertensive drugs. One patient also had type 1 diabetes.
Sustained downregulation of MIF and inflammatory parameters,
but not of HDL-cholesterol after adalimumab therapy
Serum MIF levels were significantly decreased 16 weeks after
the initiation of adalimumab therapy (median 171 pg/ml, IQR
60–444) compared with baseline (median 333 pg/ml, IQR 93–
1544, p=0.020). This effect was sustained up to week 52
(median 145, IQR 60–335, p=0.012; fig 1). CRP and ESR levels
decreased significantly after 16 and 52 weeks of adalimumab
therapy (both p,0.001, table 2).
The mean HDL-cholesterol levels increased at week 16
compared with baseline (p,0.001). However, HDL levels
returned to nearly baseline at week 52 (table 2). LDL-cholesterol
levels did not change after adalimumab treatment. Furthermore,
Lp(a) levels decreased significantly at week 16 up to week 52
after treatment (both p=0.001, table 2).
Improvement of the atherogenic index after adalimumab therapy
The mean apo A-I levels (high levels are thought to be
cardioprotective) were significantly increased to 1.56 mmol/l
(SD 0.22) at week 16 compared with 1.46 mmol/l (SD 0.25) at
baseline (p,0.001) and remained significantly elevated up to
week 52 (1.56 mmol/l, SD 0.22; p=0.005). Of interest, apo B
levels (an indicator of the total number of atherogenic particles)
did not change over the course of 52 weeks adalimumab
therapy. There was thus a significant decrease in the apo B/A-
I ratio at week 16 (p=0.014), which remained lowered up to
week 52 (p=0.050). The total cholesterol/HDL ratio showed a
temporary improvement (p=0.034), due to the increase in HDL
Figure 1 Serum macrophage migration inhibitory factor (MIF) levels
before and 16 and 52 weeks after adalimumab therapy. The median
values and ranges are shown for each time point. A large variability in
MIF concentration was observed between patients. Some high
pretreatment MIF concentrations may be due to the presence of MIF
promoter polymorphisms in certain patients. The presence of such
polymorphisms was not analysed in this study, the data, however, show
that even high baseline MIF concentrations diminish significantly after
anti-tumour necrosis factor alpha therapy.
Extended report
1318 Ann Rheum Dis 2009;68:1316–1321. doi:10.1136/ard.2007.086728levels at week 16, which had diminished again one year after the
start of treatment (table 2).
Baseline MIF concentrations and gender predict changes in MIF
after adalimumab treatment
With stepwise backward multivariable linear regression analysis
we identified baseline predictors for change in MIF levels after
treatment. Included in the analysis were the following baseline
variables: sex, BMI, MIF, CRP, triglyceride, total cholesterol and
HDL levels. No baseline predictors for change in MIF
concentration over time were identified other than patient
gender and pretreatment MIF concentrations. Baseline MIF
concentration in combination with gender predicted 45% of the
variance in change of the MIF concentration at week 16
(adjusted R
2 = 0.453). The MIF concentration at baseline alone
predicted 38% of the variance in change in the MIF concentra-
tion at week 52 (adjusted R
2 = 0.383). A significantly larger
decrease in the MIF concentration was seen in female compared
with male patients at week 16 (p=0.011), but no gender
difference was observed at week 52. We observed no association
between baseline levels of inflammation or lipid profile and
changes in MIF levels after treatment.
Changes in MIF levels and lipid profile in relation to clinical
response
We analysed whether changes in MIF concentration differ
between EULAR responders compared with non-responders. We
found no relationship between clinical response and changes in
MIF concentration at week 16 nor at week 52. However, the
decrease in the Lp(a) concentration was greater in responders
than in non-responders at week 16 (p=0.018), with a similar
trend at week 52 (p=0.087). Furthermore, in accordance with
previous data, an increase in HDL levels at week 16 was
associated with a decrease in the DAS28 score at the same time
Table 2 Changes in MIF levels and lipid profile over time
Week 0
(n = 50)
Week 16
(n = 50) p Value
Week 52
(n = 44) p Value
MIF, pg/ml (IQR) 333 (90–1544) 171 (60–444) 0.020* 145 (60–335) 0.012*
Total cholesterol, mmol/l (SD) 4.86 (1.07) 5.06 (1.16) 0.053 4.98 (1.13) 0.301
HDL-cholesterol, mmol/l (SD) 1.52 (0.38) 1.66 (0.38) ,0.001* 1.62 (0.39) 0.061
LDL-cholesterol, mmol/l (SD) 2.88 (0.95) 2.96 (1.01) 0.392 2.93 (1.02) 0.577
Triglycerides, mmol/l (SD) 1.01 (0.51) 0.99 (0.54) 0.513 0.94 (0.43) 0.350
Apo A-I, mmol/l (SD) 1.46 (0.25) 1.56 (0.22) ,0.001* 1.56 (0.21) 0.005*
Apo B, mmol/l (SD) 0.99 (0.25) 1.00 (0.27) 0.465 0.99 (0.28) 0.816
Lp(a), mmol/l (IQR) 198 (65–356) 175 (65–377) ,0.001* 171 (47–375) 0.001*
Total cholesterol/HDL (SD) 3.33 (0.93) 3.15 (0.85) 0.034* 3.19 0.84) 0.272
Apo B/Apo A-I (SD) 0.70 (0.21) 0.65 (0.20) 0.014* 0.65 (0.20) 0.050
Glucose, mmol/l (SD) 5.13 (1.97) 4.95 (1.14) 0.847 5.04 (1.34) 0.930
CRP, mg/l (IQR) 8.8 (4.6–19.6) 3.8 (1.6–9.1) ,0.001* 2.7 (1.1–5.6) ,0.001*
Values are represented as mean (SD) or median and interquartile range (IQR).
*p Values ,0.05 (two-sided) are significant.
Apo, apolipoprotein; CRP, C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Lp(a), lipoprotein (a);
MIF, macrophage migration inhibitory factor.
Figure 2 Schematic view of the
interaction between macrophage
migration inhibitory factor (MIF) and
tumour necrosis factor (TNF). Both
macrophages and T cells as well as
dendritic cells and fibroblast-like
synoviocytes produce MIF and TNF. TNF
induces the production of MIF, and vice
versa. TNF production can be induced by
MIF.
81 7In rheumatoid arthritis increased
levels of MIF and TNF have been found
locally in the synovial fluid and synovial
tissue, which perpetuate the
inflammatory process not only by
inducing further cytokine secretion, but
also by enhancing leucocyte migration
towards the site of inflammation.
18 With
anti-TNF antibody therapy available
bioactive TNF is neutralised. Furthermore,
infiltration of the inflamed synovium by
macrophages (main producers of TNF and
MIF) was shown to diminish early after
treatment.
19 Therefore, both the number of
MIF-producing cells as well as the
concentration of bioactive TNF decreases
after anti-TNF therapy, potentially leading
to a decrease in systemic MIF levels.
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16 Similarly, HDL levels increased
more in EULAR responders than in non-responders, although
this difference did not reach statistical significance (p=0.068).
The increase in apo A-I was no different between response
groups.
DISCUSSION
Both RA and atherosclerosis are related to chronic inflamma-
tion. There is increasing evidence that TNF and MIF are
involved in these conditions and that the role of these cytokines
is linked.
481 7 In both RA and atherosclerosis enhanced MIF
levels have been observed at the site of inflammation
17 20 and
MIF was shown to mediate leucocyte recruitment into the
inflamed joint and vessel wall.
18 21 Furthermore, MIF can
mediate integrin activation and induce the expression of other
inflammatory cytokines, such as IL-6, TNF and matrix
metalloproteinases, associated with joint damage in RA and
plaque instability in atherosclerosis.
21–23 The role of TNF is
supported by the observation that anti-TNF therapy may
reduce the increased cardiovascular risk associated with RA by
decreasing systemic inflammation. Previous work has shown
that TNF blockade may influence lipid levels, insulin resistance,
vascular adhesion molecule expression and endothelial func-
tion.
16 24–27 We performed the present study to provide more
insight into the mechanisms that could be involved in the
effects of anti-TNF therapy on cardiovascular risk. The results
confirm our hypothesis that adalimumab treatment leads to the
downregulation of MIF, with potential beneficial consequences
for vascular inflammation. Moreover, we show for the first time
that long-term TNF blocking therapy with adalimumab has a
favourable influence on the lipid profile of RA patients.
It has previously been suggested that chronic systemic
inflammation in RA and subsequent atherogenesis are partly
the result of chronic cytokine overflow from the inflamed joints
into the circulation.
2 Anti-TNF therapy has been shown to
diminish local inflammation in the joints by decreasing synovial
cell infiltration and the expression of adhesion molecules,
chemokines and cytokines, which coincides with a reduction
in acute phase reactants.
19 25 28 29 A decrease in CRP levels was
previously shown to be accompanied by a reduction in synovial
MIF and TNF expression in the same patient when disease
activity was reduced by conventional DMARD therapy.
30 In
light of these data we hypothesised that pro-inflammatory
cytokine release from the inflamed joint could be diminished
after adalimumab treatment, resulting in a decrease in systemic
levels of cytokines, including MIF (fig 2). Consistent with this
notion we found serum MIF levels to be significantly down-
regulated within 16 weeks after adalimumab therapy, an effect
that was sustained up to one year after the initiation of
treatment. Whether anti-TNF therapy reduces MIF in the
atherosclerotic lesion in patients is as yet unknown, but
beneficial effects of TNF inhibition on atherosclerotic lesions
have been demonstrated in animal atherosclerosis models.
31 A
decrease in MIF expression could lead to reduced monocyte and
T-cell influx into the inflamed vessel wall, hence arresting
plaque formation.
7
HDL levels increased temporarily after treatment, resulting in
an improved atherogenic index (total cholesterol/HDL-choles-
terol) at week 16, which was no longer present after one year of
adalimumab treatment. A brief rise in HDL-cholesterol, also
known as an inverse phase reaction, is to be expected after
reversing the inflammatory state and was previously reported in
other studies with infliximab.
16 32 In addition, we observed a
sustained increase in apo A-I levels and thus an improvement of
the apo B/A-I ratio. Based on these findings one can speculate
that the apo B/A-I ratio may better reflect the cardiovascular
risk profile after TNF blocking therapy than the traditional
atherogenic index (total cholesterol/HDL), as differential effects
of adalimumab therapy can be observed for apo A-I and HDL
levels. Of interest, serum apo A-1 has previously been shown to
inhibit T-cell contact-induced monocyte activation.
33 As a result
cytokine (TNFa and IL-1b) production by monocytes was
inhibited while monocyte proliferation remained unaltered.
These data indicate a novel anti-inflammatory mechanism of
this apolipoprotein. Conceivably, the sustained increase of apo
A-1 levels in our study might lead to the inhibition of T-cell-
induced monocyte activation, both in the inflamed synovium
and in the vessel wall.
Lp(a) has been demonstrated to have a spectrum of
pathogenic activities among which are increased vascular
adhesion molecule expression, chemotaxis of monocytes, foam
cell formation, smooth muscle cell proliferation and increased
platelet aggregation. Different clinical studies have shown Lp(a)
levels to be an independent risk factor for developing CHD.
34 35
The significant decrease in levels of Lp(a) both 16 and 52 weeks
after adalimumab therapy could thus contribute to a decrease in
the pro-atherogenic state. This could be a direct effect of anti-
TNF therapy but may also be an indirect effect of the overall
diminishment in inflammation.
The open-label rather than placebo-controlled design is
obviously a limitation of this study, as we cannot conclude
with complete certainty that the decease in MIF levels resulting
from decreased inflammation was a direct effect of TNF
blockade or merely a result of regression to the mean.
However, the patients had persistent disease activity in spite
of at least two conventional DMARD before inclusion in the
study, suggesting that the reduction in inflammation was the
result of TNF blockade. The data presented in this exploratory
study thus provide the rationale for future studies with a
controlled design to confirm the effects on lipid profiles and MIF
levels in relation to cardiovascular endpoints.
In conclusion, TNF blocking therapy reduced systemic MIF
levels, possibly reflecting a reduction in the atherogenic state.
Apart from reduced systemic inflammation, as shown by
reduced CRP and ESR levels, the sustained decrease in the apo
B/apo A-I ratio suggests a favourable effect of adalimumab
treatment on markers associated with atherogenesis.
Acknowledgements: The investigators would like to thank the research nurses
Margot Colombijn and Mariane Anson for performing the clinical assessments and
Laura Splint for performing the MIF ELISA.
Funding: This study was supported by Abbott Laboratories.
Competing interests: PPT is a member of the advisory board of Abbott and has
received honoraria for lectures. The study sponsors had no involvement in the study
design, the collection, analysis and interpretation of the data, writing the report, or the
decision to submit the paper for publication.
Ethics approval: Approval for this study was obtained from the institutional ethics
review committee at the Academic Medical Center/University of Amsterdam.
Patient consent: Obtained.
REFERENCES
1. van Leuven SI, Franssen R, Kastelein JJ, Levi M, Stroes ES, Tak PP. Systemic
inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford)
2008;47:3–7.
2. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how ‘‘high-grade’’ systemic
inflammation accelerates vascular risk in rheumatoid arthritis. Circulation
2003;108:2957–63.
3. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868–74.
4. Morand EF, Leech M, Bernhagen J. MIF: a new cytokine link between rheumatoid
arthritis and atherosclerosis. Nat Rev Drug Discov 2006;5:399–410.
Extended report
1320 Ann Rheum Dis 2009;68:1316–1321. doi:10.1136/ard.2007.0867285. Herder C, Illig T, Baumert J, Muller M, Klopp N, Khuseyinova N, et al. Macrophage
migration inhibitory factor (MIF) and risk for coronary heart disease: Results from the
MONICA/KORA Augsburg case–cohort study, 1984–2002. Atherosclerosis
2008;200:380–8.
6. Boekholdt SM, Peters RJ, Day NE, Luben R, Bingham SA, Wareham NJ, et al.
Macrophage migration inhibitory factor and the risk of myocardial infarction or death
due to coronary artery disease in adults without prior myocardial infarction or stroke:
the EPIC–Norfolk Prospective Population study. Am J Med 2004;117:390–7.
7. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, et al. MIF is a
noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell
recruitment. Nat Med 2007;13:587–96.
8. Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important
and previously unrecognized source of macrophage migration inhibitory factor. J Exp
Med 1994;179:1895–902.
9. Popa C, van Lieshout AW, Roelofs MF, Geurts-Moespot A, van Riel PL, Calandra T, et
al. MIF production by dendritic cells is differentially regulated by Toll-like receptors
and increased during rheumatoid arthritis. Cytokine 2006;36:51–6.
10. Niessner A, Shin MS, Pryshchep O, Goronzy JJ, Chaikof EL, Weyand CM.
Synergistic proinflammatory effects of the antiviral cytokine interferon-alpha and
Toll-like receptor 4 ligands in the atherosclerotic plaque. Circulation
2007;116:2043–52.
11. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, et al. Toll-like receptor-4
is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques
and upregulated by oxidized LDL. Circulation 2001;104:3103–8.
12. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in
patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173–7.
13. van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease-
modifying antirheumatic drugs are associated with a reduced risk for cardiovascular
disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther
2006;8:R151.
14. Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, et al.
Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis.
Ann Rheum Dis 2007;66:670–5.
15. Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Reduction in
the incidence of myocardial infarction in patients with rheumatoid arthritis who
respond to anti-tumor necrosis factor alpha therapy: results from the British Society
for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905–12.
16. Popa C, van den Hoogen FH, Radstake TR, Netea MG, Eijsbouts AE, den Heijer M, et
al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy
in patients with active rheumatoid arthritis. Ann Rheum Dis 2007;66:1503–7.
17. Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M, et al. Macrophage
migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory
function and regulation by glucocorticoids. Arthritis Rheum 1999;42:1601–8.
18. Gregory JL, Leech MT, David JR, Yang YH, Dacumos A, Hickey MJ. Reduced
leukocyte-endothelial cell interactions in the inflamed microcirculation of macrophage
migration inhibitory factor-deficient mice. Arthritis Rheum 2004;50:3023–34.
19. Smeets TJ, Kraan MC, van Loon ME, Tak PP. Tumor necrosis factor alpha blockade
reduces the synovial cell infiltrate early after initiation of treatment, but apparently not
by induction of apoptosis in synovial tissue. Arthritis Rheum 2003;48:2155–62.
20. Onodera S, Tanji H, Suzuki K, Kaneda K, Mizue Y, Sagawa A, et al. High expression
of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints.
Cytokine 1999;11:163–7.
21. Schober A, Bernhagen J, Thiele M, Zeiffer U, Knarren S, Roller M, et al. Stabilization
of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after
vascular injury in apolipoprotein E-deficient mice. Circulation 2004;109:380–5.
22. Amin MA, Haas CS, Zhu K, Mansfield PJ, Kim MJ, Lackowski NP, et al. Migration
inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular
adhesion molecule-1 via Src, PI3 kinase, and NFkappaB. Blood 2006;107:2252–61.
23. Radstake TR, Sweep FC, Welsing P, Franke B, Vermeulen SH, Geurts-Moespot A, et
al. Correlation of rheumatoid arthritis severity with the genetic functional variants and
circulating levels of macrophage migration inhibitory factor. Arthritis Rheum
2005;52:3020–9.
24. Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab
treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing
spondylitis. Ann Rheum Dis 2005;64:765–6.
25. Tak PP, Taylor PC, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, et al. Decrease in
cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha
monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum
1996;39:1077–81.
26. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN. Deactivation
of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in
rheumatoid arthritis. Arthritis Rheum 1996;39:1082–91.
27. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, et al. Anti-tumor
necrosis factor-alpha treatment improves endothelial function in patients with
rheumatoid arthritis. Circulation 2002;106:2184–7.
28. Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R, et al.
Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor
alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:38–47.
29. Ulfgren AK, Andersson U, Engstrom M, Klareskog L, Maini RN, Taylor PC. Systemic
anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates
synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 2000;43:2391–6.
30. Morand EF, Leech M, Weedon H, Metz C, Bucala R, Smith MD. Macrophage
migration inhibitory factor in rheumatoid arthritis: clinical correlations. Rheumatology
(Oxford) 2002;41:558–62.
31. Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of
tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout
mice. Arterioscler Thromb Vasc Biol 2004;24:2137–42.
32. Popa C, Barrea P, Netea MG, Stalenhoef AF, van der Meer JW. Anti-TNF therapy
and plasma HDL cholesterol concentration. Atherosclerosis 2005;182:375.
33. Hyka N, Dayer JM, Modoux C, Kohno T, Edwards CK III, Roux-Lombard P, et al.
Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis
factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes.
Blood 2001;97:2381–9.
34. Seman LJ, DeLuca C, Jenner JL, Cupples LA, McNamara JR, Wilson PW, et al.
Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study.
Clin Chem 1999;45:1039–46.
35. Luc G, Bard JM, Arveiler D, Ferrieres J, Evans A, Amouyel P, et al. Lipoprotein (a) as
a predictor of coronary heart disease: the PRIME Study. Atherosclerosis
2002;163:377–84.
Extended report
Ann Rheum Dis 2009;68:1316–1321. doi:10.1136/ard.2007.086728 1321